Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric FLT3 Wild-Type Newly Diagnosed AML

Liposomal-encapsulated daunorubicin/cytarabine (CPX-351), which has shown benefit in adults with secondary AML, unexpectedly failed to demonstrate efficacy in pediatric patients with newly diagnosed FLT3 wild-type acute myeloid leukaemia. The findings, published in the Journal of Clinical Oncology, challenge the assumption that the formulation's advantages in adult AML would translate to the pediatric FLT3 wild-type population. This negative result has important implications for treatment strategy in childhood AML and underscores the need for age- and genotype-specific trial design rather than extrapolation from adult data.